Unlike traditional anticoagulants like warfarin, rivaroxaban does not require routine coagulation monitoring due to its predictable pharmacokinetic profile. However, in cases of suspected overdose or toxicity, specific assays such as anti-Factor Xa activity can be used to assess the drug's anticoagulation effect. Clinical evaluation remains paramount in assessing bleeding risks and therapeutic efficacy.
